Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared and then assessed using whole-cell, patch-clamp electrophysiology for their anticonvulsant activities in animal seizure models and for their sodium channel activities. We found compounds with various substituents at the terminal aromatic ring that had excellent anticonvulsant activity. Of these compounds, (R)-N-4′-((3″-chloro)phenoxy)benzyl 2-Nacetamido-3-methoxypropionamide ((R)-5) and (R)-N-4′-((3″-trifluoromethoxy)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-9) exhibited high protective indices (PI = TD 50 / ED 50 ) comparable with many antiseizure drugs when tested in the maximal electroshock seizure test to mice (intraperitoneally) and rats (intraperitoneally, orally). Most compounds potently transitioned sodium channels to the slow-inactivated state when evaluated in rat embryonic
Introduction
The epilepsies are serious, neurological disorders that affect up to 1% of the world's population. 1 Although more than 40 drugs have been used to treat these disorders, 2 significant health needs remain unmet. First, current antiseizure drugs (ASDs) are ineffective for about one-third of patients, even when multiple drugs are prescribed. 3 Second, ASD use is associated with untoward side effects in more than 40% of patients, ranging from common cosmetic (e.g., gingival hyperplasia, weight gain) and quality of life (e.g., sedation, learning, cognitive dysfunction) to rare, life-threatening (e.g., hepatotoxicity, aplastic anemia) ones. 4, 5 Third, some epilepsies, such as Lenox-Gestault and mesial temporal lobe epilepsy, worsen over time, and for these disorders, there is a need for a disease-modifying drug. 6 Finally, most seizure medications do not address associated comorbidities (e.g., cognitive dysfunction 7 ). Thus, the need still remains for ASDs that have novel mechanism(s) of action with safe profiles.
We have reported on a novel series of chimeric compounds, (R)-A, [8] [9] [10] derived from the merger of key structural units (Fig. 1B, C ) present in the functionalized amino acid (FAA), lacosamide 11 ((R)-N-benzyl 2-N-acetamido-3-methoxypropionamide, (R)-1) and the α-aminoamide (AAA), safinamide 12, 13 ((S)-2-(4′-((3″-fluoro)benzyloxy)benzyl)aminopropionamide, (S)-2). Lacosamide is a first-in-class ASD that is extensively used for the treatment of partial-onset seizures in adults. 14 Safinamide, another anticonvulsant, 15 has been advanced for the treatment of Parkinson's disease. 16 Studies have shown that safinamide inhibits monoamine oxidase type B, 17 thus likely preventing dopamine bioactivation in patients suffering from Parkinson's disease. We demonstrated that select (R)-A compounds displayed potent anticonvulsant activities in the maximal electroshock 18 (MES) and the 6-Hz psychomotor 19 seizure assays in rodents. [8] [9] [10] The anticonvulsant activities of (R)-A have been attributed, in part, to their actions on voltage-gated sodium channel (VGSC) properties. 9, 10, 20 Chimeric compounds (R)-A potently transitioned VGSCs to the slow-inactivated state and in some cases, affected fast inactivation processes and inhibited Na + currents in a frequency (use)-dependent fashion. The experimental findings for slow inactivation by (R)-A were also consistent with a mechanism in which the chimeric compounds block fast-inactivated channels with very slow kinetics. 21, 22 26 using the MAC reagents isobutylchloroformate (IBCF) and N-methylmorpholine (NMM) to give amides (R)-28 -(R)-33, respectively, without racemization of the C(2) chiral center. The substituted 4-phenoxybenzylamines were prepared by treating 4-fluorobenzonitrile (10) with the appropriate aryl phenol (11 -15) using either K 2 CO 3 or Cs 2 CO 3 in DMF to give the corresponding nitriles. [24] [25] [26] [27] Subsequent reduction of the nitrile group in 16 -20 with LiAIH 4 afforded the amines 22 -26. The corresponding unsubstituted 4-phenoxybenzylamine (21) was commercially available. Methylation (CH 3 I, Ag 2 O) of the serine hydroxyl group in (R)-28 -(R)-33 provided ethers (R)-34 -(R)-39, respectively. Deprotection of the tert-butoxycarbonyl group in (R)-34 -(R)-39 with acid (HCI/dioxane) followed by acetylation (AcCI, Et 3 N) gave the desired products (R)-3 and (R)-5 -(R)-9, respectively. The enantiomeric purities of (R)-3 and (R)-5 -(R)-9 were assessed by the detection of a single acetyl methyl peak and a single O-methyl peak in the 1 H NMR spectrum for each compound when a saturated solution of (R)-(−)-mandelic acid was added. 28 We report, in the Experimental Section, the details (synthetic procedure, characterization) of the final step for all compounds evaluated in the seizure and cellular electrophysiology studies. In the Supporting Information, we provide the experimental procedures and the physical and full spectroscopic properties for all the synthetic compounds prepared in this study.
Pharmacological evaluation

Whole animal pharmacological activity-Compounds (R)-3 and (R)-5 -(R)-9
were tested for anticonvulsant activity at the Anticonvulsant Screening Program (ASP) of the National Institute of Neurological Disorders and Stroke (NINDS), U.S. National Institutes of Health, using the procedures described by Stables and Kupferberg. 29 The anticonvulsant data from the MES model 18 (mice, intraperitoneally (ip); rat, ip; rat, orally (po)), and the psychomotor 6 Hz (32 mA) seizure test for therapy-resistant limbic seizures 19 (mice, ip) are summarized in Table 1 31 and valproate. 31 For compounds that showed significant activity, we report the 50% effective dose (ED 50 ) values from quantitative screening evaluations. We also include the median doses for 50% neurological impairment (TD 50 ) in mice, using the rotorod test, 33 and the behavioral toxicity effects observed in rats. 34 The protective index (PI = TD 50 /ED 50 ) for the test compounds is listed, where possible. Compounds (R)-4 -(R)-6, (R)-8 and (R)-9 were evaluated in the subcutaneous Metrazol (scMet) seizure model, 35 and no activity was observed below 40 mg/kg (data not shown). Similarly, we found no activity in the scMet model for (R)-1 11 and structurally related compounds. [8] [9] [10] 36 Compounds (R)-3 -(R)-9 displayed excellent activities in the MES model in mice when administered ip and in rats when administered either ip or po. For most compounds, we observed in mice (ip) ED 50 values that ranged from 5.5 -14 mg/kg, values that were comparable with the ASDs (R)-1 11 and phenytoin 31, 32 (ED 50 2.3.2. Whole-cell, patch-clamp electrophysiological activity-The well-described mechanisms of action by lacosamide and safinamide, parents of (R)-D series compounds, both involve inhibition of VGSCs. 14, 15, 37, 38 Promising anticonvulsant activities of (R)-3 -(R)-9 therefore prompted our examination of the VGSC activities in rat embryonic cortical neurons 9,10,39 by whole-cell, patch-clamp electrophysiology. These neurons typically express central nervous system (CNS) sodium channel isoforms Na v 1.1, Na v 1.2, Na v 1.3, and Na v 1.6. 40 Kinetic properties of slow inactivation, frequency (use)-dependence, and steady-state activation and fast inactivation of Na + currents were measured in the presence of (R)-3 -(R)-9. The cortical neurons were grown for 7-10 days in vitro and then examined using protocols described earlier. 9, 10, 39 Compounds (R)-3 -(R)-9 were tested only at 10 μM due to constraints of cortical neuron viability during the course of the patch-clamp experiments. Here, we did not separate the exact contribution of the four Na v isoforms in the presence of (R)-3 -(R)-9 because of the lack of subtype-specific blockers of these Na v isoforms, and the possible interactions between said blockers of various Na v channels and the (R)-D compounds themselves. Thus, we assumed contributions from all four CNS Na v isoforms. The excellent anticonvulsant activity observed for (R)-9 led us to examine this compound further in both catecholamine A-differentiated (CAD) cells 41 that express predominantly Na v 1.7 and in recombinant HEK293 cells that express hNa v 1.1, rNa v 1.3, hNa v 1.5, or hNa v 1.7 channels. 9 2.3.2.1. Rat embryonic cortical neurons: First, we tested the ability of 10 μM (R)-3 -(R)-9 to modulate the transition of VGSCs to a slow-inactivated state. Cortical cells were conditioned to potentials ranging from −100 mV to +20 mV (in +10 mV increments) for 5 s. 9, 39, 42 Channels that underwent fast inactivation during this conditioning pulse were then allowed to recover during a 1 second pulse to −70 mV before the extent of slow inactivation was examined by a test pulse to −10 mV, for 20 ms ( Fig. 2A, left) . Representative traces illustrating the extent of slow inactivation observed at −50 mV compared to the prepulse at −100 mV in the absence (control) or presence of (R)-5 and (R)-8 are shown in Figure 2A (right), with the full slow inactivation curve (normalized peak versus prepulse potential) of (R)-5 shown in Figure 2B . At 10 μM, (R)-5 facilitated the transition of a majority of sodium channels into the slow-inactivated state compared with control (0.1% DMSO)-treated neurons. Slow inactivation at −50 mV was chosen as a point of comparison between compounds due to the physiological relevance of this voltage near the resting membrane potential and action potential firing threshold of neruons. At this voltage, VGSC activation and inactivation kinetics mediate channel availability that determines if sustained firing, akin to that during an epileptic event, is possible. [43] [44] [45] [46] [47] At −50 mV, a small fraction (i.e., 0.16 ± 0.05 n=5; calculated as 1 minus the normalized I Na ) of the channels had entered a slowinactivated conformational state(s) in control-treated cells (Fig. 2B, C) . Compared with the control, (R)-3 -(R)-9 caused a significant decrease in the maximal fraction of current that is available by depolarization, with maximal induction observed in the presence of (R)-3 (0.82 ± 0.03, n=5) (p <0.01, Mann-Whitney U test).
We next interrogated if (R)-3 -(R)-9 could enhance steady-state fast inactivation. For these studies we used a similar protocol (Fig. 3, top left) designed to induce a fast-inactivated state. 9 Cells were subjected to inactivating prepulse potentials ranging from −100 to −10 mV (in 10-mV increments) for 500 ms prior to a 0 mV test pulse for 20 ms to estimate the extent of fast inactivation. The 500 ms conditioning pulse allows for examination of the linear range of fast inactivation curves for endogenous channels at assayed potentials. Steady-state, fast inactivation curves of Na + currents from control (0.1% DMSO)-and (R)-3 -(R)-9-treated cortical neurons were well fitted with a single Boltzmann function (R 2 > 0.963 for all conditions). The value of voltage of half-maximal inactivation (V 1/2 ) for 0.1% DMSOtreated cells was −53.4 ± 1.5 mV (n=4), which was not significantly different from that observed for (R)-3 -(R)-9 (p>0.05 vs. control; Student's t-test; Fig. 3 ).
Next, we tested whether (R)-3 -(R)-9 could alter the voltage-dependence of activation for cortical neuron VGSCs. Activation changes for cortical neurons treated with compounds were measured by whole-cell ionic conductances in response to changes in command voltage (Fig. 3, top right) and analyzed by comparing Boltzmann properties of half maximal activation (V 1/2 ) and slope factors (k). 9, 39 Boltzmann fits for 0.1% DMSO (control) and (R)-3 -(R)-9 are shown in Figure 3 . The V 1/2 value for steady-state activation for 0.1% DMSO-treated (control) neurons was −27.1 ± 1.3 mV (n=5), which was significantly different from that of (R)-7 (−35.6 ± 4.1 mV; n=5) and (R)-8 (−36.8 ± 1.0 mV; n=6) (p<0.05 vs. control; Student's t-test; Fig. 3 
) but not for (R)-3 -(R)-6 and (R)-9.
Finally, we tested if (R)-3 -(R)-9 could elicit frequency (use)-dependent blockage of Na + currents. The ability to block Na + currents in an activity-or use-dependent manner is a useful property for ASDs since it allows for preferential decreases in sodium channel availability during high-(i.e., seizures) but not low-frequency firing. 48 Thirty, identical test pulses were applied at 10 Hz (Fig. 4A) . 9, 39 The difference in available current was calculated by dividing the peak current at any given pulse (pulse N ) by the peak current in response to the initial pulse (pulse 1 ). Representative currents for this protocol are shown for control and 10 μM (R)-7-treated cells (Fig. 4B ). None of the tested compounds exhibited statistically relevant frequency (use)-dependent inhibition of Na + currents (Fig. 4C ).
The anticonvulsant activity for (R)-9 led us to further explore the electrophysiological properties of this compound in CAD and HEK293 recombinant cells, which express a distinct population of Na v channels.
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CAD cells:
CAD cells express endogenous tetrodotoxin-sensitive Na + currents that display rapid activation and inactivation kinetics upon membrane depolarization 39 and are likely composed mostly of Na v 1.7 channels with minor contributions by Na v 1.1, Na v 1.3, and Na v 1.9 channels. 9, 42, 49 We showed that the sodium channel properties of (R)-1 in CAD cells 49 are similar to those in cultured neurons and in mouse N1E-115 neuroblastoma cells. 50 CAD cells were easily recorded from and cultured thus allowing us to conveniently determine (R)-9 sodium channel slow inactivation, frequency (use)-dependence, and steadystate activation and fast inactivation properties over a range of concentrations. These properties were quantitatively compared with other (R)-A compounds, (R)-1, and (S)-2. Compound (R)-9 promoted VGSC transition to a slow-inactivated state in a concentrationdependent manner; almost complete slow inactivation was observed at the highest concentration (Fig. 5A ). To determine the comparative level to which (R)-9 induced slow inactivation, we calculated concentration response curves for slow inactivation induction at −50 mV as well as at +20 mV; the IC 50 inactivation values are shown in Figure 5A (boxes). Compared with our recently reported IC 50 values of 85 and 13 μM for slow inactivation induced by (R)-1 9,20 and (S)-2, 10 the IC 50 value for (R)-9 (0.70 μM) was ~121-fold and ~19-fold lower, respectively, at −50 mV. Similar differences in the IC 50 values were measured at +20 mV. Next, we tested for the effects of (R)-9 on fast inactivation. We used a protocol tailored to induce a fast-inactivated state, as previously described. 9, 10, 20 Cells were subjected to prepulse potentials ranging from −120 to −10 mV in 10 mV increments for 500 ms. A 0 mV test pulse for 20 ms measures the available current. The 500 ms conditioning pulse allows for examination of the linear range of fast inactivation curves for endogenous channels at assayed potentials. As illustrated in Figure 5B , steady-state, fast inactivation curves of Na + currents from control (0.1% DMSO) and CAD neurons treated with various concentrations of (R)-9 were well fitted with a single Boltzmann function (R 2 > 0.979 for all conditions). The V 1/2 value for inactivation for 0.1% DMSO (control)-treated cells was −69.1 ± 3.6 mV (n=7), which was significantly different from that of (R)-9 (10 μM)-treated cells (−84.6 ± 1.6 mV; n=6; p<0.05; Student's t-test; Fig. 5B ). Because changes in Na + current amplitudes could be due to alterations in channel gating, 51 we tested if (R)-9 altered the voltage-dependent activation properties of Na + currents. Activation changes for CAD cells treated with (R)-9 were measured by whole-cell ionic conductances in response to changes in command voltage and analyzed by comparing Boltzmann properties of midpoints (V 1/2 ) and slope factors (k). We found that VGSC steady-state activation properties were no different between 0.1% DMSO (control; V 1/2 for activation = −19.5 ± 2.8 mV (n=8)) and any concentration tested for (R)-9 ( Fig. 5B ). Finally, we tested if (R)-9 could confer frequency (use)-dependent Na + current block. Thirty, identical test pulses were applied at 10 Hz as described previously. 9, 10, 20 The available current in control cells (0.1% DMSO) and treated cells (various concentrations of (R)-9) was calculated by dividing the peak current at any given pulse (pulse N ) by the peak current in response to the initial pulse (pulse 1 ). Compound (R)-9 exhibited frequency (use)-dependent inhibition of Na + currents (Fig. 5C) , and by the last pulse, compared with control (0.1% DMSO), the peak current was ~39% lower in the presence of 10 μM (R)-9. When we tested 30 μM (R)-10 in a similar protocol, we observed ~44% inhibition in Na + currents (data not shown).
HEK293 Recombinant cells:
In order to test if (R)-9 had effects on various sodium channel isoforms, we examined the effects of 10 μM (R)-9 on slow inactivation, fast inactivation, steady-state activation, and frequency (use)-dependence in HEK293 cells that stably expressed CNS (hNa v 1.1, rNa v 1.3), peripheral nervous system (hNa v 1.7), and cardiac (hNa v 1.5) channels using voltage protocols 9 illustrated in Figure 6A , K. The results of these experiments are summarized in Table 2 . Notably, (R)-9 exhibited similar, though not identical, effects on these biophysical properties irrespective of sodium channels, indicating that this compound exhibited little isoform specificity. We observed that (R)-9 robustly transitioned the four sodium channel subtypes to the slow-inactivated state; that (R)-9 shifted the V 1/2 of fast inactivation for Na v 1.7 by ~20.2 mV in the hyperpolarizing directon without affecting V 1/2 values for any of the other channel isoforms; and that (R)-9 had no effect on steady-state activation or on frequency (use)-inhibition of Na + currents carried by any of the Na v 1.x channels. 19, 55 and the mouse corneal kindling and the rat hippocampal tests are considered to be predicative models for partial-onset and partial complex seizures. 52 Next, we evauated (R)-9 (10 μM) against a panel of seven human CYP450 enzymes and observed little or no direct inhibition for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 (data not shown). We found little or no time-dependent inhibition of these enzymes other than for CYP2C8 by (R)-9, for which there was an ~16% inhibition increase after a 30-min preincubation period. We also determined the pharmacokinetic properties for (R)-9 in Sprague-Dawley rats (iv, po). Using a single iv dose of 5 mg/kg and an oral dose of 20 mg/kg, (R)-9 showed excellent bioavailability (92%) and where the t 1/2 (iv) value was 1.75 h, the t 1/2 (po) value was 4.63 h, and the brain:plasma ratio was 1.2:1 at 6.0 h.
Additional studies-Among the (R)-D compounds, (R)-
Compound (R)-9 was evaluated at UNC's NIMH Psychoactive Drug Screening Program (PDSP) 56 against a battery of 43 receptors known to adversely impact drug effectiveness. No significant binding was observed at 10 μM. Moreover, (R)-9 did not affect hERG K + channel activity (Patch Express) at 30 μM (data not shown). Finally, we conducted a non-GLP 7-day repeated dose toxicity study for (R)-9 in Sprague-Dawley female rats upon oral (gavage) administration at 20, 60, and 180 mg/kg/day dose levels. The no observed adverse effect level (NOAEL) for (R)-9 was 60 mg/kg/day, providing a NOAEL/MES ED 50 value of ~10. At higher dose levels, effects were observed in the ability to bear weight, coordination in gait, respiratory rate, relative organ weight (e.g., increase in liver, decrease in spleen and thymus), clinical chemistry parameters, and gross pathology (data not shown).
Discussion
Many 10 inhibited Na + currents in a frequency (use)-dependent manner, but unlike these two, we observed that (R)-9 affected fast inactivation at the highest concentration (10 μM) tested (Fig. 5) . These overall results suggest that the composition and size of the different linkers in (R)-D -(R)-F did not appreciably affect the interaction of the chimeric compounds with the VGSCs.
Our finding that (R)-9 promoted sodium channel slow inactivation in rat embryonic cortical neurons that express Na v 1.1, Na v 1.2, Na v 1.3, and Na v 1.6 channels 36 and in CAD cells that largely express Na v 1.7 channels 9, 42, 49 suggested that this compound showed little Na v channel subtype selectivity. We explored this by testing (R)-9 in HEK293 recombinant cells 9 that expressed hNa v 1.1, rNa v 1.3, hNa v 1.5, or hNa v 1.7 (Fig. 6 ). In agreement with this notion, (R)-9 (10 μM) potently transitioned the sodium channels to the slow-inactivated state regardless of the Na v channel isoform. In the recombinant cells, we observed that the effect of (R)-9 was different on sodium channel fast inactivation and frequency (use)-dependent inhibition. A similar result was previously reported for a (R)-E compound where X = Cl. 9 The anticonvulsant activities for the (R)-D compounds are attributed, in part, to their ability to modulate VGSC activities. Using rat embryonic cortical neurons that express Na v 1.1, Na v 1.2, Na v 1.3, and Na v 1.6 channels, 40 we learned that the (R)-D compounds uniformly promoted slow inactivation (Fig. 2) . At 10 μM, the 3″-unsubstituted derivative (R)-3 was the most potent, followed by the 3″-electron-withdrawing derivatives (R)-4, (R)-5, (R)-9, (R)-7, and then the two 3″-electron-donating derivatives (R)-6 and (R)-8 (Fig. 2C ). Interestingly, the relative level of slow inactivation for the (R)-D compounds did not parallel their corresponding anticonvulsant activities. For example, (R)-3 showed the greatest level of slow inactivation (Fig. 2C ), but it was the least potent in the MES seizure model in mice (ip) ( Table 1 ). When we compared the slow inactivation IC 50 (−50 mV) values for (R)-9 and (R)-1 in CAD cells, we found that the IC 50 value for (R)-9 was 0.70 μM, which was ~120-fold lower than the value reported for (R)-1 (85 μM). Despite (R)-9's increased potency, we did not find a comparable increased protection for (R) We tentatively attribute this finding to the multiple factors that contribute to whole animal pharmacological activity, the sodium channel composition in CAD cells versus those in the CNS, the possibility that additional, unidentified pathways exist for seizure control, and the recognition that patchclamp electrophysiology studies do not recapitulate conditions created in the seizure models.
Conclusion
Many of the chimeric (R)-D compounds displayed potent anticonvulsant activities and high PI values, which were similar to ASDs, in the MES test when administered to rodents. The chimeric compounds' anticonvulsant activities likely stemmed, at least in part, from their ability to promote sodium channel slow inactivation. VGSCs are responsible for the initiation of and the sustained activity of neuronal signaling during seizure events. The well described mechanism of action for both (R)-D parent compounds, lacosamide and safinamide, involve inhibition of these channels. 14,15,37,38 Phenytoin, lamotrigine, and carbamazepine are among other ASDs that have primary activity on VGSCs to restrict neuronal firing during seizures. 57 As evident by perturbation of VGSC slow inactivation (Fig. 2) , the class (R)-D compounds potently shifted VGSC availability, which readily explains anticonvulsant activity. The type of channel block produced by these compounds is also a desirable characteristic for ASDs. By selectively affecting sodium channel slow inactivation or frequency (use)-dependent block, these compounds can promote channel inhibition in response to sustained use (i.e., epileptic activity).
Experimental
General methods
Melting points were determined in open capillary tubes using a Thomas-Hoover melting point apparatus and are uncorrected. Optical rotations were obtained on a Jasco P-1030 polarimeter at the sodium D line (589 nm) using a 1 dm path length cell. NMR spectra were obtained at 400 MHz ( 1 H) and 100 MHz ( 13 C) using TMS as an internal standard. Chemical shifts (δ) are reported in parts per million (ppm) from tetramethylsilane. Low-resolution mass spectra were obtained with a BioToF-II-Bruker Daltonics spectrometer by Dr. S. Habibi at the University of North Carolina Department of Chemistry. The high-resolution mass spectrum was performed on a Bruker Apex-Q 12 Telsa FTICR spectrometer by Dr. S. Habibi. Microanalyses were performed by Atlantic Microlab, Inc. (Norcross, GA). Reactions were monitored by analytical thin-layer chromatography (TLC) plates (Aldrich, Cat # Z12272-6) and analyzed with 254 nm UV light. The reactions were purified by flash column chromatography using silica gel (Dynamic Adsorbents Inc., Cat # 02826-25). All chemicals and solvents were reagent grade and used as obtained from commercial sources without further purification. Yields reported are for purified products and were not optimized. Compounds were checked by TLC, 1 H and 13 C NMR, MS, and elemental analyses. The analytical results are within ±0.40% of the theoretical value. The TLC, NMR and the analytical data confirmed the purity of the products was ≥95%. The resulting residue was dissolved in CH 2 Cl 2 (0.1-0.3 M) and then triethylamine (2-3 equiv) and acetyl chloride (1.0-1.2 equiv) were carefully added at 0 °C and the resulting solution was stirred at room temperature (2-16 h). The solution was washed with an aqueous 10% citric acid solution followed by a saturated aqueous NaHCO 3 solution. The organic layer was dried (Na 2 SO 4 ) and concentrated in vacuo. The residue was purified by column chromatography on SiO 2 and/or recrystallized with EtOAc/hexanes. 7.32-7.48 (m, 2 ArH), addition of excess (R)-(−)-mandelic acid to a CDCl 3 solution of (R)-7 gave only one signal for the acetyl methyl and one signal for the methoxy protons; 13 
General procedure for the deprotection and acetylation of (R)-N-benzyl 2-N-(tert-butoxycarbonyl)amino-3-methoxypropionamide derivatives (R)-34 -(R)-39 to give (R)-3 and (R)-5 -(R)-9 (Method 1)-A CH
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Pharmacology
Compounds were screened under the auspices of the National Institutes of Health's ASP. Experiments were performed in male rodents (albino Carworth Farms No. 1 mice (ip), albino Sprague-Dawley rats (ip, po)). Housing, handling, and feeding were in accordance with recommendations contained in the Guide for the Care and Use of Laboratory Animals. Anticonvulsant activity was established using the MES test, 18 6 Hz, 19 and the scMet test, 35 according to previously reported methods. 8,11
Catecholamine A-differentiated (CAD) cells
CAD cells were grown at 37 °C and in 5% CO 2 (Sarstedt, Newton, NC) in Ham's F12/ DMEM (GIBCO, Grand Island, NY), supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO) and 1% penicillin/streptomycin (100% stocks, 10,000 U/mL penicillin G sodium and 10,000 μg/mL streptomycin sulfate). 49 Cells were passaged every 3-5 days at a 1:5 dilution.
Cortical neurons
Rat cortical neuron cultures were prepared from cortices dissected from embryonic day 19 cortices exactly as described. 58, 59 5.5. Culturing HEK293 cells expressing Na v 1.1, Na v 1.3, Na v 1.5, and Na v 1.7
Na v 1.1, Na v 1.3, Na v 1.5, and Na v 1.7 stable cells were grown under standard tissue culture conditions (5% CO 2 at 37 °C) in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (100% stocks, 10,000 U/mL penicillin G sodium and 10,000 μg/mL streptomycin sulfate) as described before. 9
Electrophysiology
Whole-cell voltage clamp recordings were performed at room temperature on cortical neurons, CAD cells, and HEK293 cells expressing Na v 1.x isoforms using an EPC 10 Amplifier (HEKA Electronics, Lambrecht/Pfalz Germany) as described previously. 9, 10, 20 Electrodes were fabricated from thin-walled borosilicate glass capillaries (Warner Instruments, Hamden, CT) with a P-97 electrode puller (Sutter Instrument, Novato, CA) such that final electrode resistances were 1-2 MΩ when filled with internal solutions. The internal solution for recording Na + currents contained (in mM Whole-cell capacitance and series resistance were compensated with the amplifier. Series resistance error was always compensated to be less than ± 3 mV. Cells were considered for analysis only when the access resistance was less than 3 MΩ. Linear leak currents were digitally subtracted by −P/4 leak subtraction.
Data acquisition and analysis
Signals were filtered at 10 kHz and digitized at 10-20 kHz. Analysis was performed using Fitmaster and origin8.1 (OriginLab Corporation, MA, USA). For activation curves, conductance (G) through sodium channels was calculated using the equation G = I/(V m − V rev ), where V rev is the reversal potential, V m is the membrane potential at which the current was recorded and I is the peak current. Activation and inactivation curves were fitted to a single-phase Boltzmann function G/G max = 1/{1+exp[(V−V 50 )/k]}, where G is the peak conductance, G max is the fitted maximal G, V 50 is the half-activation voltage, and k is the slope factor. Additional details of specific pulse protocols are described in the results text or figure legends.
Statistical analyses
Differences between means were compared by either paired or unpaired, two-tailed Student's t-tests or an analysis of variance (ANOVA), when comparing multiple groups (repeated measures whenever possible). If a significant difference was determined by ANOVA, then a Dunnett's or Tukey's post-hoc test was performed. Data are expressed as mean ± SEM, with p<0.05 considered as the level of significance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Table 2 Comparative current densities, cell capacitances, and Boltzmann parameters of voltage-dependence of channel activation and steady-state fast inactivation curves for control-and (R)-N-4′-((3″-trifluoromethoxy)phenoxy)benzyl (R)-2-acetamido-3-methoxypropionamide ((R)-9)-treated HEK293 cells expressing Na V 1.1, Na V 1.3, Na V 1.7 or Na V 1.5 channels. 
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